17 June 2017 - The president could use his deal-making skills to negotiate voluntary pricing restraints for the industry.

The affordability of prescription drugs is a growing public concern, as annual drug spending continues to rise year after year. Recent pricing scandals, including the 6,000% increase in the pediatric muscular dystrophy drug Deflazacort, along with Martin Shkreli’s 5,000% increase in the toxoplasmosis treatment Daraprim, only fuel the public outcry.

On numerous occasions, President Donald Trump has vowed to take action to constrain drug prices. Although the specifics of Trump’s plans to lower prices are reportedly being hammered out as I write, the wrong action could have disastrous effects.

Read Bloomberg article